Menin is a brake the beta cell releases on purpose: pregnancy and glucose both lower it
also called physiological menin downregulation · menin prolactin beta cell · glucose represses menin
Insulin-making cells keep menin around to stop themselves multiplying, but when the body needs more insulin - in pregnancy, or when blood sugar is high - the cell deliberately lowers its own menin so it can divide. Losing menin for a while is therefore something the healthy beta cell does to itself, not only something a disease does to it.
The same thing, for a scientist
Menin restrains beta-cell proliferation, and that restraint is physiologically regulated rather than fixed. In pregnant mice islet menin falls and beta cells proliferate; forcing menin to stay high in maternal beta cells prevents islet expansion and produces hyperglycaemia and impaired glucose tolerance - i.e. experimental gestational diabetes - and prolactin is sufficient to repress islet menin and stimulate proliferation [E1]. An independent pregnancy study places the fall at about 50% in wild-type islets and shows it is blunted in prolactin-receptor heterozygotes [E2]. High glucose likewise lowers menin in INS-1 cells, primary rat islets and islets from glucose-infused rats, via PI3K/Akt/Foxo1 acting on the Men1 promoter, and menin overexpression blocks the glucose-induced proliferation [E3]. This is the single most important piece of context for the whole menin-inhibitor endocrine-toxicity argument: a transient, partial, reversible reduction of menin in the beta cell is a normal adaptive event, not an inherently oncogenic one.
What each experiment actually shows
- Pregnancy (mouse). Maternal islet beta cells proliferate; islet menin and its targets fall. A transgene that keeps menin expressed in maternal beta cells prevents the expansion and causes hyperglycaemia and impaired glucose tolerance. Prolactin represses islet menin and stimulates proliferation 1.
- Pregnancy, prolactin-receptor dose (mouse). Islet menin falls by ~50% in Prlr(+/+) and only ~20% in Prlr(+/-) between day 0 and day 15 of pregnancy, alongside phospho-Jak2 and phospho-Akt induction and p18/p21 changes 2.
- Glucose (rat, cell line, in vivo infusion). Menin falls in high-glucose INS-1 cells and primary rat islets, and in islets from rats given a 72-h glucose infusion; blockade of PI3K/Akt prevents the fall; Foxo1 binds the Men1 promoter and raises menin transcription; menin overexpression abolishes the glucose-driven proliferation 3.
Why this matters for a child on a menin inhibitor
The toxicity argument in this beat runs: menin is a tumour suppressor, so removing it is dangerous. These three papers add a necessary qualifier - the beta cell removes its own menin routinely and reversibly, and the consequence is adaptive growth, not neoplasia. Physiological down-regulation is partial (roughly 50% in pregnancy 2), time-limited, and terminates when the stimulus ends. A pharmacological inhibitor is also partial and time-limited, but it blocks a binding pocket rather than lowering protein level, and it does so on a schedule the cell did not choose. Whether pocket blockade is read by the cell as the same signal as reduced menin abundance is not established by any of these papers and is the load-bearing unknown.
The part that does not comfort
None of this says the release is free. In the same physiology, the cost of an unrestrained release is visible: complete beta-cell Men1 ablation gives hyperplastic islets by 2 months and insulinomas by 6 with full penetrance (see concept-men1-loss-to-endocrine-tumour-latency). Physiological release is bounded by a stimulus that ends; pharmacological release is bounded only by the prescriber. The relevant variable is therefore duration and depth of release, not its existence.
| tissue | pancreatic islet beta cell |
|---|---|
| direction | menin is physiologically down-regulated to permit proliferation |
| magnitude | approximately 50% fall in islet menin at day 15 of mouse pregnancy |
| human evidence | none of these three papers has a human arm |
stimuli
[ "pregnancy / prolactin", "hyperglycaemia" ]
species
[ "mouse", "rat" ]
- If menin down-regulation is the beta cell's own growth signal, a menin inhibitor is a growth signal delivered continuously and without the off-switch the physiological version has.
- The paediatric beta cell has a higher baseline replication rate than the adult's, so a proliferative stimulus that is harmless in a 60-year-old may not be in a 2-year-old, and no trial measures it.
- This mechanism predicts that patients on a menin inhibitor should show measurable changes in insulin secretion. Neither approved label reports a single glucose or insulin parameter, so the prediction is currently untestable from public data.
- Does a clinical menin inhibitor at an approved dose reproduce the transcriptional state of physiological menin down-regulation, or a different state? Nobody has compared the two by RNA-seq in the same islet preparation.
- Is there a depth or duration of menin release beyond which the beta cell does not return to quiescence when the stimulus ends?
- Does the paediatric beta cell, which is already more proliferative than the adult's, sit closer to that threshold?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Islet menin falls during pregnancy and forcing it to stay high prevents beta-cell expansion and causes gestational-diabetes-like hyperglycaemia in mice.
Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. · Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, et al. · Science 2007What this evidence cannot show
Mouse; transgenic overexpression is a gain-of-function manipulation, so it shows menin is sufficient to block expansion, not that the physiological fall is necessary in every context. Pregnancy is a hormonal state with no paediatric counterpart.
Evidence that argues against this (1)
- The same regulation shows menin loss is proliferative: in other models beta-cell Men1 ablation proceeds beyond adaptive hyperplasia to full-penetrance insulinoma, so a fall in menin is not intrinsically benign - it is benign when it is bounded. Li F et al. 2015
- E2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Islet menin falls by about 50% during mouse pregnancy in a prolactin-receptor-dose-dependent way.
Participation of Akt, menin, and p21 in pregnancy-induced beta-cell proliferation. · Hughes E, Huang C · Endocrinology 2011What this evidence cannot show
Expression-level study in isolated islets; associative with respect to proliferation, and the percentage fall is from immunoblot quantification in a small number of animals.
Evidence that argues against this (1)
- This paper measures menin alongside Jak2/Akt/p18/p21 and does not isolate menin's contribution; the proliferative phenotype could be driven by the other arms of prolactin-receptor signalling. Karnik SK et al. 2007
- E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
High glucose represses menin via PI3K/Akt/Foxo1 and thereby promotes beta-cell proliferation.
Glucose-mediated repression of menin promotes pancreatic beta-cell proliferation. · Zhang H, Li W, Wang Q, Wang X, Li F, Zhang C, et al. · Endocrinology 2012What this evidence cannot show
Rat INS-1 cells, primary rat islets and a 72-h rat glucose infusion; no human islet arm and no in vivo proliferation-to-mass readout.
Evidence that argues against this (1)
- Chronic glucose exposure is itself a beta-cell stressor and the proliferative response is transient; sustained menin repression in the same tissue is what drives the MEN1 tumour phenotype. Harding B et al. 2009
Menin restrains beta-cell proliferation and is itself down-regulated by pregnancy/prolactin and by glucose (Karnik 2007; Zhang 2012)
Adds a third exposure class the latency entry does not consider: bounded, reversible, physiological ~50% menin reduction that the healthy beta cell performs on itself without neoplasia
the molecular content of the brake that the beta cell releases on purpose
- ← related toThe endocrine cell's resting state is an actively maintained G1 restraint, and menin is what maintains it
the physiological release of the same state